首页 | 本学科首页   官方微博 | 高级检索  
   检索      

多巴胺通过促进RNF20降解抑制神经细胞中组蛋白H2B泛素化
引用本文:董婷婷,刘艳萍,李云芳,李胜,张国安,刘增甲,黄鑫,崔文.多巴胺通过促进RNF20降解抑制神经细胞中组蛋白H2B泛素化[J].中国生物化学与分子生物学报,2019,35(4):421-427.
作者姓名:董婷婷  刘艳萍  李云芳  李胜  张国安  刘增甲  黄鑫  崔文
作者单位:(1)青岛大学基础医学院法医学,山东 青岛266000;2)西安交通大学医学部法医学院,西安710061;3)济南大学 山东省医学科学院医学与生命科学学院,山东 济南250022;4) 济宁医学院法医学与医学检验学院,山东 济宁272067)
基金项目:国家级大学生创新训练计划项目(No.201710443001);济宁医学院教师科研扶持基金 (No.JY2017FY003);济宁医学院贺林院士新医学临床转化工作站科研基金(No.JYHL2018MS14)
摘    要:表观遗传修饰参与了药物成瘾的形成过程,而在药物成瘾过程中组蛋白泛素化水平的变化仍未可知。药物成瘾过程中常表现为多巴胺(dopamine, DA)表达量的升高,因此本研究欲探讨多巴胺升高对神经细胞组蛋白泛素化的影响及其机制。Western印迹结果显示,在终浓度0.8 mmol/L的多巴胺作用8 h后,人神经母细胞瘤细胞系SH-SY5Y细胞中环指蛋白20(ring finger protein 20, RNF20)表达量降低(0.29±0.032 vs. 1.0±0.025,P<0.0001),泛素化组蛋白H2B(H2Bub1)表达量下降(0.28±0.032 vs. 1.0±0.017,P<0.0001)。但是RT-PCR结果显示,多巴胺处理SH-SY5Y细胞后,RNF20在mRNA水平的表达无明显变化。在SH-SY5Y细胞中沉默RNF20的表达,H2Bub1在蛋白质水平的表达明显降低(0.20±0.069 vs. 1.0±0.060,P=0.001)。在加入多巴胺的基础上,分别加入蛋白酶体抑制剂MG132、自噬体形成抑制剂3-MA以及空泡型H^+-ATP酶特异性抑制剂Baf-A1等药物来检测RNF20的降解途径,结果发现,加入MG132、3-MA以及Baf-A1后,RNF20表达量均比DA处理组显著上升(1.51±0.095,P=0.0003; 0.89±0.075,P=0.0021; 2.74±0.099,P<0.0001;vs. 0.27±0.044)。上述结果表明,在SH-SY5Y细胞中,RNF20对H2Bub1具有调控作用,多巴胺可通过泛素化及自噬两种途径促进RNF20降解,从而抑制组蛋白H2B泛素化。

关 键 词:多巴胺  SH-SY5Y细胞  环指蛋白20  泛素化  自噬
收稿时间:2018-11-01

Dopamine Inhibits the Ubiquitination of Histone H2B in Nerve Cells by Promoting RNF20 Degradation
DONG Ting-Ting,LIU Yan-Ping,LI Yun-Fang,LI Sheng,ZHANG Guo-An,LIU Zeng-Jia,HUANG Xin,CUI Wen.Dopamine Inhibits the Ubiquitination of Histone H2B in Nerve Cells by Promoting RNF20 Degradation[J].Chinese Journal of Biochemistry and Molecular Biology,2019,35(4):421-427.
Authors:DONG Ting-Ting  LIU Yan-Ping  LI Yun-Fang  LI Sheng  ZHANG Guo-An  LIU Zeng-Jia  HUANG Xin  CUI Wen
Institution:(Department of Forensic Medicine, Basic Medical College, Qingdao University, Qingdao 266000, China;School of Forensic Medicine, Xi′an Jiao Tong University Health Science Center, Xi′an 710061, China;School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan 250062, China;Affiliated Hospital of Jining Medical University Institute of Forensic Medicine and Laboratory Medicine of Jining Medical University, Jining 272067, China)
Abstract:Epigenetic modification is involved in the formation of drug addiction, however, it is still unclear whether the level of histone ubiquitination is affected in the process of drug addiction. In the process of drug addiction, the production of dopamine is often increased, but the effect of dopamine on histone ubiquitination remains unknown. This study focused on the effect of dopamine on histone ubiquitination during drug addiction. Western blot showed that after treatment of 0.8 mmol/L dopamine for 8 h, the production of ring finger protein 20 (RNF20) in SH-SY5Y human neuroblastoma cells was decreased (0.29 ± 0.032 vs. 1.0 ± 0.025, P< 0.0001),and the production of ubiquitinated histone H2B (H2Bub1) also decreased (0.28 ± 0.032 vs. 1.0 ± 0.017, P< 0.0001). However, RT-PCR results showed that there were no significant differences in mRNA levels of RNF20 expression after SH-SY5Y cells were treated with dopamine. Silence of RNF20, significantly decreased the production of H2Bub1 at the protein level in SH-SY5Y cells (0.2 ± 0.069 vs. 1.0 ± 0.060, P =0.001). Combined with dopamine, proteasome inhibitor MG132, autophagy inhibitor 3-MA, or vacuolar H+-ATPase specific inhibitor Baf-A1 were added respectively to detect the degradation of RNF20. The results showed that the production of RNF20 increased significantly in groups treated with DA combined with MG132, 3-MA and Baf-A1 as compared with those treated only with DA (1.51 ± 0.095, P=0.0003; 0.89 ± 0.075, P=0.0021; 2.74 ± 0.099, P< 0.0001 vs. 0.27 ± 0.044). These results indicated that dopamine inhibited histone H2B ubiquitination by degrading RNF20 through ubiquitination and autophagy in SH-SY5Y cells.
Keywords:dopamine(DA)  SH-SY5Y cells  ring finger protein  20(RNF20)  ubiquitination  autophagy  
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《中国生物化学与分子生物学报》浏览原始摘要信息
点击此处可从《中国生物化学与分子生物学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号